Wire · opportunities
Freenome SimpleScreen Blood-Based Colorectal Cancer Screening Test Gets FDA Approval
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 28 July 2026 · Fusion42 review
Freenome's SimpleScreen, a blood-based colorectal cancer screening test, has received FDA approval. The approval comes one week after the company's SPAC IPO.
This Wire brief sits within Fusion42's coverage of Diagnostics. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.
◆ ◆ The Wire takeaway
Freenome just cleared the regulatory gate for a non-invasive colorectal cancer screen. If you build supporting infrastructure—lab software, sample logistics, reporting platforms—a newly FDA-cleared test now needs to scale from lab to clinical adoption, and Freenome's public status means it has capital to build or buy integrations.
◆ Related on Wire
◆ Topics